Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Raymond James Downgrades Centerspace to Market Perform

Raymond James Downgrades Centerspace to Market Perform

Raymond James analyst Buck Horne downgrades Centerspace (NYSE:CSR) from Outperform to Market Perform.

byBenzinga Newsdesk

August 4, 2022

1 minute read

Raymond James analyst Buck Horne downgrades Centerspace (NYSE:CSR) from Outperform to Market Perform.

SVB Leerink Reiterates Outperform on Sarepta Therapeutics, Maintains $160 Price Target

By Benzinga Newsdesk

January 20, 10:14 AM

SVB Leerink analyst Joseph Schwartz reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $160 price target.

SRPT

Newell Brands Slashes Office Roles By 7% In Major Organizational Shake-Up: Details

By Shivani Kumaresan

January 8, 1:14 PM

Consumer products maker Newell Brands Inc (NASDAQ: NWL) plans an organizational realignment to strengthen

NWL

Eni Earnings Conference Call Is Coming Up, Here’s What You Need To Know

By Benzinga Insights

July 25, 7:43 AM

Eni (NYSE:E) will host a conference call at 08:00 AM ET on July 29, 2022, to discuss Q2 2022 earnings results. How to Attend Eni (E) Conference Call Follow this link to access the live webcast.

JPMorgan Challenges Class-Action Status For Jeffrey Epstein’s Accusers

By Bibhu Pattnaik

May 13, 3:14 PM

JPMorgan Chase & Co (NYSE: JPM) has appealed to a federal judge to reject a class-action status request by one of Jeffrey Epstein's accusers, who accused the bank of enabling the late

JPM

Raymond James Downgrades Centerspace to Market Perform

Related Posts

SVB Leerink Reiterates Outperform on Sarepta Therapeutics, Maintains $160 Price Target

Newell Brands Slashes Office Roles By 7% In Major Organizational Shake-Up: Details

Eni Earnings Conference Call Is Coming Up, Here’s What You Need To Know

JPMorgan Challenges Class-Action Status For Jeffrey Epstein’s Accusers